VCYT:NSD-Veracyte Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 33.51

Change

+0.16 (+0.48)%

Market Cap

USD 2.71B

Volume

0.54M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+11.27 (+2.26%)

USD 41.71B
ICLR ICON PLC

+2.21 (+0.78%)

USD 25.10B
ILMN Illumina Inc

+6.12 (+4.85%)

USD 20.90B
NTRA Natera Inc

-1.14 (-0.91%)

USD 15.80B
EXAS EXACT Sciences Corporation

+0.17 (+0.25%)

USD 13.09B
MEDP Medpace Holdings Inc

+5.68 (+1.77%)

USD 11.34B
RDNT RadNet Inc

-1.81 (-2.55%)

USD 5.13B
SHC Sotera Health Co

N/A

USD 4.69B
NEOG Neogen Corporation

+0.21 (+1.28%)

USD 3.78B
GH Guardant Health Inc

+0.43 (+1.93%)

USD 3.09B

ETFs Containing VCYT

GNOM Global X Genomics & Biote.. 4.44 % 0.00 %

+0.16 (+0.53%)

USD 0.08B
ARCG:LSE ARK Genomic Revolution UC.. 4.38 % 0.00 %

+0.30 (+0.53%)

USD 3.03M
ARKG:LSE ARK Genomic Revolution UC.. 4.34 % 0.00 %

+0.03 (+0.53%)

USD 3.09M
GNOG:LSE Global X Genomics & Biote.. 4.29 % 0.00 %

N/A

USD 6.06M
ARKG 4.27 % 0.75 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 4.00 % 0.00 %

-0.01 (0.53%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.00 % 0.00 %

-0.02 (0.53%)

USD 6.06M
THNQ Robo Global® Artificial .. 2.35 % 0.00 %

+0.76 (+0.53%)

USD 0.13B
AIAG:LSE L&G Artificial Intelligen.. 2.35 % 0.00 %

N/A

USD 0.70B
AIAI:LSE L&G Artificial Intelligen.. 2.35 % 0.00 %

+0.32 (+0.53%)

USD 0.70B
DOCG:LSE L&G Healthcare Breakthrou.. 2.17 % 0.00 %

+3.00 (+0.53%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.17 % 0.00 %

-0.01 (0.53%)

USD 0.07B
HTEC Robo Global® Healthcare .. 2.17 % 0.00 %

+0.52 (+0.53%)

USD 0.06B
XMLH:XETRA L&G Healthcare Breakthrou.. 1.96 % 0.00 %

+0.09 (+0.53%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.96 % 0.00 %

+0.02 (+0.53%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.96 % 0.00 %

+0.01 (+0.53%)

USD 0.07B
WBIO:LSE WisdomTree BioRevolution .. 1.88 % 0.00 %

+1.80 (+0.53%)

USD 3.87M
WDNA 1.82 % 0.00 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.07 (0.53%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.06 (0.53%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.05 (0.53%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.30 % 0.00 %

-0.04 (0.53%)

N/A
ETHO Amplify ETF Trust 0.52 % 0.45 %

+0.66 (+0.53%)

USD 0.18B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

+0.39 (+0.53%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.81% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.81% 78% C+ 79% B-
Trailing 12 Months  
Capital Gain 46.27% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.27% 82% B 83% B
Trailing 5 Years  
Capital Gain 38.30% 75% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.30% 75% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 9.63% 62% D 66% D+
Dividend Return 9.63% 62% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.97% 54% F 33% F
Risk Adjusted Return 17.84% 74% C 53% F
Market Capitalization 2.71B 74% C 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector